

VHL Polyclonal Antibody

Description

Product type	Primary Antibody
Code	BT-AP15472
Host	Rabbit
Isotype	IgG
Size	20ul, 50ul, 100ul
Immunogen	The antiserum was produced against synthesized peptide derived from the N-terminal region of human VHL. AA range:1-50
Mol wt	N/A
Species reactivity	Human, Rat, Mouse
Clonality	Polyclonal
Recommended application	IHC-p, IF, ELISA
Concentration	1 mg/ml
Full name	Von Hippel-Lindau disease tumor suppressor
Synonyms	Von Hippel-Lindau disease tumor suppressor ;Protein G7;pVHL; Von Hippel-Lindau disease tumor suppressor; Protein G7; pVHL


This product is for research use only, not for use in human, therapeutic or diagnostic procedure.

Background

Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of this gene is the basis of familial inheritance of VHL syndrome. The protein encoded by this gene is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein. Alternatively spliced transcript variants encoding distinct isoforms have been observed.

Recommended Dilution

IHC-p: 1: 50 - 1: 200 ELISA: 1: 10000 - 1: 20000 Not yet tested in other applications.



Immunohistochemical analysis of paraffin-embedded human-colon, antibody was diluted at 1:200

Immunohistochemical analysis of paraffin-embedded human-colon, antibody was diluted at 1:200

501 Changsheng S Rd, Nanhu Dist, Jiaxing, Zhejiang, China

Tel: 86 21 31007137 | E-mail: save@bt-laboratory.com | www.bt-laboratory.com